A phase II study of the efficacy, safety and immunogenicity of OncoVexGM-CSF in patients with stage IIIc and stage IV malignant melanoma.
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors BioVex
- 03 Nov 2009 Results reported online in the Journal of Clinical Oncology.
- 16 May 2008 Interim results reported in a BioVex media release.
- 16 May 2008 The abstract describing interim results is now available at www.asco.org